MOUNJARO TIRZEPATIDE 12.5MG INJECTIONS - AN OVERVIEW

The demo accomplished the two its Key endpoints, with semaglutide 2.4 mg demonstrating statistically major and superior improvements in liver fibrosis with no worsening of steatohepatitis, in addition to resolution of steatohepatitis without any worsening of liver fibrosis in individuals with MASH as compared to placebo.1Pancreatitis and gallbladde